IGPH.SW IGEA Pharma (SIX) down 25% pre-market to CHF 0.0015 03 Feb 2026: liquidity risk

IGPH.SW stock opened the pre-market session on 03 Feb 2026 at CHF 0.0015, down 25.00% from the prior close. Trading is heavy with 2,033,000 shares reported so far, roughly ten times average volume, flagging it as one of the most active names on the SIX pre-market list. Investors should note the company’s tiny market cap (around CHF 505,545.00), negative EPS (-0.03) and weak liquidity metrics. This article breaks down price action, fundamentals, Meyka AI grade and short-term trade outlook for IGEA Pharma N.V. (IGPH.SW) on the SIX in Switzerland.

IGPH.SW stock pre-market price action and volume

The stock opened at CHF 0.0015 and hit an early high of CHF 0.002 before retreating. Volume is 2,033,000 shares versus an average of 193,941, giving a relative volume of roughly 10.48x. The intraday move matched a reported one-day change of -25.00%. High relative volume with a sub-penny price increases execution risk and slippage for larger orders.

Company snapshot and fundamentals

IGEA Pharma N.V. (IGPH.SW) lists on the SIX and operates in Healthcare, focused on diagnostics and med-tech. Market cap is about CHF 505,545.00 with 337,030,016 shares outstanding. Trailing EPS is -0.03 and the reported PE is -0.05, reflecting losses. The 50-day average price is CHF 0.00214 and the 200-day average is CHF 0.00517, showing a long downtrend versus the Healthcare sector average PE of 34.55. Current ratio is weak at 0.19, flagging short-term liquidity pressure.

Technical view, liquidity and Meyka AI grade

Technically the stock trades near its year low of CHF 0.0005 and well below the year high of CHF 0.05. Order book depth is thin given the low price and small market cap. Meyka AI rates IGPH.SW with a score out of 100: 58.59 (Grade C+), suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade highlights poor liquidity and negative cashflow metrics but counts potential product footholds in diagnostics.

Valuation, cash flow and key risks

Key ratios show stressed fundamentals: price/book is negative at about -0.24, EV/EBITDA is negative, and operating cash flow per share is -0.00119. Cash per share is minimal at 0.00008886. These figures point to cash burn and solvency risk without fresh capital. Major risks include continued dilution, thin trading liquidity, and limited product commercialization scale in a competitive med-tech sector.

Trading outlook and most active strategy

As a most active pre-market pick, IGPH.SW is a volatility play, not a core holding. Short-term traders can focus on tight risk controls, limit orders and small position sizes. Watch intraday spreads and VWAP. Institutional investors will likely avoid due to market cap and poor liquidity. Sector news on diagnostics or a capital raise would move the stock materially.

Meyka AI forecast and scenario targets

Meyka AI’s forecast model projects CHF 0.00 over the measured horizon. Compared with the current price of CHF 0.0015, that implies an effective downside of -100.00% under the model baseline. Scenario price targets for traders: conservative bear CHF 0.0005 (down 66.67%), recovery case CHF 0.0050 (up 233.33%), extreme downside CHF 0.0001 (down 93.33%). Forecasts are model-based projections and not guarantees.

Final Thoughts

IGPH.SW stock presents a high-risk, high-volatility trading profile in the pre-market on 03 Feb 2026. The immediate picture is weak: a 25.00% pre-market drop to CHF 0.0015, very high relative volume (~10.48x) and minimal market capitalization (~CHF 505,545.00) amplify execution and dilution risk. Fundamentals show negative EPS (-0.03), poor current ratio (0.19) and negative cash flow per share (-0.00119). Meyka AI’s proprietary grade is 58.59 (C+, HOLD), reflecting weak financials but recognition of the company’s med-tech exposure. Meyka AI’s forecast model projects CHF 0.00, which implies a model baseline with no material recovery; this is a model output, not a prediction. For active traders the path is event-driven: watch corporate updates, sector announcements, and any capital raise. For longer-term investors, the balance of risks (liquidity, dilution) vs opportunities (diagnostics products) suggests caution. Always size positions small and use limit orders when trading low-price, low-cap names. Meyka AI is the AI-powered market analysis platform used to derive the grade and model outputs cited above. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.